VIMIZIM, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

VIMIZIM

Elosulfase Alfa

Prescription required

$1625.00

5mg · 5 vial

BrandBranded medicine· By BioMarin

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

FDA boxed warningHypersensitivity reactions including anaphylaxis and risk of acute respiratory complications

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.

Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring.

If a severe hypersensitivity reaction (anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine.

Read this with the rest of the clinical information

About VIMIZIM

Overview

VIMIZIM contains elosulfase alfa, an enzyme made using recombinant DNA technology. It is used to treat mucopolysaccharidosis type IVA (MPS IVA), also called Morquio A syndrome. It works by supplying an enzyme that is missing or has reduced activity in this condition, helping cells break down substances called glycosaminoglycans that would otherwise build up.

What it treats

Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.

Safety information

Side effects

Common side effects include fever, vomiting, headache, nausea, abdominal pain, chills and tiredness. Serious risks include hypersensitivity reactions, including anaphylaxis (a severe allergic reaction), acute breathing complications, and compression of the spinal cord, including in the neck. Seek urgent medical help for a severe allergic reaction or breathing difficulty, and contact a doctor promptly if spinal cord compression is suspected. Tell your doctor before an infusion if you have an illness with fever or a respiratory illness. These may increase the risk of life-threatening complications from a hypersensitivity reaction. Your doctor may consider delaying the infusion.

FDA boxed warning

Hypersensitivity reactions including anaphylaxis and risk of acute respiratory complications

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate VIMIZIM in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.

Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring.

If a severe hypersensitivity reaction (anaphylaxis) occurs, discontinue VIMIZIM and immediately initiate appropriate medical treatment, including use of epinephrine.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

- Seek immediate medical attention if breathing problems suddenly worsen, especially if you have a respiratory illness. - Seek immediate medical attention for a severe allergic reaction (anaphylaxis). This can occur early in treatment or after long-term treatment.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The label lists no contraindications to Vimizim. Patients with an acute illness involving fever or breathing problems may be at higher risk of life-threatening complications from hypersensitivity reactions. The treating clinician should carefully assess the patient’s condition before administration and consider delaying the infusion.

Using VIMIZIM

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VIMIZIM (ELOSULFASE ALFA) INJECTION, SOLUTION, CONCENTRATE [BIOMARIN PHARMACEUTICAL INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines